While each day brings fresh updates on the progress of companies developing vaccines to fight COVID-19, which are rightly seen as the most powerful weapon against the novel coronavirus, the potential of novel antibody cocktails is also being explored at pace by biopharma companies, government and academic researchers.
The promise is that a mix of two or more antibodies, either discovered in the lab or based on antibodies taken from patients who have recovered from COVID-19, can fix on two distinct locations on the receptor binding domain of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?